Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management

David M. Thomas, Brian O'Sullivan, Alessandro Gronchi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care. They can occur anywhere in the retroperitoneal abdominal or pelvic space. Usually large at presentation they present particular challenges for both local treatment and systemic control. The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma). A variety of additional histotypes may also be observed, but are uncommon in the retroperitoneum, either because of intrinsic rarity or because they are usually found in other anatomic sites. The underlying biology varies according to the different histotypes. Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/ pPNET and alveolar rhabdomyosarcoma. Surgery is critical for controlling these tumors and requires an aggressive approach. It may also provide useful palliation for patients with advanced slow-growing disease. Radiotherapy has acquired a definite position in attempting to reduce relapse, although prospective trials of adjuvant or neoadjuvant radiotherapy are needed. Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease. Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.

Original languageEnglish
Pages (from-to)1145-1157
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume9
Issue number8
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Sarcoma
Liposarcoma
Radiotherapy
Histiocytoma
Alveolar Rhabdomyosarcoma
Pediatrics
Ewing's Sarcoma
Leiomyosarcoma
Neoplasms
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Chemotherapy
  • Prognosis
  • Radiotherapy
  • Retroperitoneal sarcoma
  • Sarcoma
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. / Thomas, David M.; O'Sullivan, Brian; Gronchi, Alessandro.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 8, 08.2009, p. 1145-1157.

Research output: Contribution to journalArticle

@article{a52dded440994d75855c9c528e26196c,
title = "Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management",
abstract = "Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care. They can occur anywhere in the retroperitoneal abdominal or pelvic space. Usually large at presentation they present particular challenges for both local treatment and systemic control. The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma). A variety of additional histotypes may also be observed, but are uncommon in the retroperitoneum, either because of intrinsic rarity or because they are usually found in other anatomic sites. The underlying biology varies according to the different histotypes. Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/ pPNET and alveolar rhabdomyosarcoma. Surgery is critical for controlling these tumors and requires an aggressive approach. It may also provide useful palliation for patients with advanced slow-growing disease. Radiotherapy has acquired a definite position in attempting to reduce relapse, although prospective trials of adjuvant or neoadjuvant radiotherapy are needed. Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease. Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.",
keywords = "Chemotherapy, Prognosis, Radiotherapy, Retroperitoneal sarcoma, Sarcoma, Surgery, Survival",
author = "Thomas, {David M.} and Brian O'Sullivan and Alessandro Gronchi",
year = "2009",
month = "8",
doi = "10.1586/ERA.09.77",
language = "English",
volume = "9",
pages = "1145--1157",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management

AU - Thomas, David M.

AU - O'Sullivan, Brian

AU - Gronchi, Alessandro

PY - 2009/8

Y1 - 2009/8

N2 - Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care. They can occur anywhere in the retroperitoneal abdominal or pelvic space. Usually large at presentation they present particular challenges for both local treatment and systemic control. The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma). A variety of additional histotypes may also be observed, but are uncommon in the retroperitoneum, either because of intrinsic rarity or because they are usually found in other anatomic sites. The underlying biology varies according to the different histotypes. Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/ pPNET and alveolar rhabdomyosarcoma. Surgery is critical for controlling these tumors and requires an aggressive approach. It may also provide useful palliation for patients with advanced slow-growing disease. Radiotherapy has acquired a definite position in attempting to reduce relapse, although prospective trials of adjuvant or neoadjuvant radiotherapy are needed. Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease. Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.

AB - Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care. They can occur anywhere in the retroperitoneal abdominal or pelvic space. Usually large at presentation they present particular challenges for both local treatment and systemic control. The most common adult subtypes are liposarcomas and leiomyosarcomas, followed by pleomorphic sarcoma/malignant fibros histiocytoma (an entity not always easily distinguishable from dedifferentiated liposarcoma). A variety of additional histotypes may also be observed, but are uncommon in the retroperitoneum, either because of intrinsic rarity or because they are usually found in other anatomic sites. The underlying biology varies according to the different histotypes. Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/ pPNET and alveolar rhabdomyosarcoma. Surgery is critical for controlling these tumors and requires an aggressive approach. It may also provide useful palliation for patients with advanced slow-growing disease. Radiotherapy has acquired a definite position in attempting to reduce relapse, although prospective trials of adjuvant or neoadjuvant radiotherapy are needed. Chemotherapy has a limited role in the adjuvant setting for most forms of retroperitoneal sarcoma (excluding pediatric subtypes), but has an increasing role in advanced disease. Novel targeted therapeutic agents that target specific amplification or translocation products offer promise for subsets of these diseases.

KW - Chemotherapy

KW - Prognosis

KW - Radiotherapy

KW - Retroperitoneal sarcoma

KW - Sarcoma

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=70350637496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350637496&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.77

DO - 10.1586/ERA.09.77

M3 - Article

VL - 9

SP - 1145

EP - 1157

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 8

ER -